Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed ... and the thymic stromal lipoprotein (TSLP) receptor, which is a key regulator of dendritic cell ...

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 10.08%, which has investors questioning if this is right time to sell.

Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash ...

The FDA has already approved phase 2 trials of solrikitug, a monoclonal antibody targeting TSLP, in patients with chronic obstructive pulmonary disease (COPD) and asthma. This should get underway ...

Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education ...

About ATI-052 ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets ...